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Objective/background: The aim of this study is to determine the rate of hookworm infection
among patients with pulmonary tuberculosis (TB) and to find out if there is a relation
between hookworm infection and the therapeutic failure of pulmonary TB.
Methods: We carried out a prospective, hospital-based study. The study included 231 naı¨ve
patients with pulmonary TB, consecutively. Patients were evaluated at the 4th month of
therapy for persistence of Mycobacterium tuberculosis infection. All patients had clinical
evaluation, laboratory investigations (including sputum culture and stool microscopic
examination), and imaging studies (abdominal ultrasonography and chest radiography).
Results: The study population mean age was 42.7 ± 13.9 years old with 26.8% of them
40 years old or more. Out of 231 patients, 133 (57.6%) were men. Therapeutic failure rate
of pulmonary TB was 29.4%. Hookworm infection was diagnosed among 16.5% of patients
and 27.7% had diabetes mellitus (DM). Using multivariate analysis, it was found that age of
40 years or more (odds ratio [OR] 8.4; 95% confidence interval [CI] 1.7–41.3; p = .009),
hookworm infection (OR 7.6; 95% CI 1.2–49.9; p = .034), and DM (OR 5.9; 1.2–28; p = .027) were
independently associated with therapeutic failure of pulmonary TB among the study
population with pulmonary TB.
Conclusion: In conclusion, the rate of therapeutic failure of pulmonary TB is high. Besides
older age and DM, hookworm infection can reduce the therapeutic response of pulmonary
TB. Screening for and control of DM and hookworm infection among patients with
pulmonary TB may improve their therapeutic response.
 2015 Asian African Society for Mycobacteriology. Production and hosting by Elsevier Ltd.
All rights reserved.iut, 71515,
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Introduction
Tuberculosis (TB) is a major global health problem, with an
estimated 9 million new cases and 1.5 million deaths during
2013 according to the World Health Organization (WHO) [1].
The standard four-drug regimen (isoniazid, rifampin, etham-
butol, and pyrazinamide for 2 months followed by isoniazid
and rifampin for 4 months) has high efficacy in achieving cure
rates (90–95%) [2]. To monitor pulmonary TB patients, culture
examinations are recommended at monthly intervals until
two consecutive culture specimens are negative at the end
of treatment [3]. According to WHO, the therapeutic failure
of pulmonary TB is defined as positive sputum culture at
the 4thmonth or later during treatment [4]. The gold standard
for the diagnosis of TB is culture [5].
More than 500 million people are infected with hookworm
globally. The diagnosis of hookworm infection is made with
microscopic identification of the characteristic ova in stool
[6]. The overlapping distribution of hookworm infection with
other pathogens results in a high rate of coinfection [7]. It was
speculated that helminth infections, including hookworm,
may adversely influence the host–immune response to other
infections, especially to intracellular pathogens such as
Mycobacterium tuberculosis (Mtb) [8,9]. This has lead to the
suggestion that helminth infection may increase both the
susceptibility to, and the disease progression of, bacterial
diseases. This hypothesis is based on the observation that
helminth infections results in eosinophilia, elevated
immunoglobulin E, and mast cell activation, suggestive of
the enhanced cytokine response by type 2-T-helper cells
(Th2) and a concomitant suppression of a type 1-T-helper
cells (Th1) response, which is often involved in the protection
against intracellular pathogens [10].
Both pulmonary TB and hookworm infections are com-
mon diseases in Egypt. The therapeutic failure of pulmonary
TB is not uncommonly encountered in upper Egypt. We lack
studies exploring the impact of hookworm infection on the
rate of therapeutic failure among patients with pulmonary
TB. The aim of this study is to determine the rate of hook-
worm infection among patients with pulmonary TB, and to
find out if there is a relation between hookworm infection
and the therapeutic failure of pulmonary TB.
Materials and methods
We carried out a prospective, hospital-based study at Assiut
University Hospital during the period of June 2011 to
November 2014. The study included 231 naı¨ve patients with
pulmonary TB, consecutively. Pulmonary TB was diagnosed
based on positive sputum culture on Lo¨wenstein–Jensenmed-
ium performed by an experienced microbiologist, with or
without evidence on chest radiography [5]. All patients
received the WHO-recommended therapy: isoniazid
(5 mg/kg/day), rifampin (10 mg/kg/day; maximum dose was
600 mg/day), ethambutol (20 mg/kg/day; maximum dose was
1600 mg/day), and pyrazinamide (30 mg/kg/day; maximum
dose was 2000 mg/day) for 2 months, followed by isoniazidand rifampin for 4 more months [11]. Therapeutic failure of
4th month or later during treatment [4]. The diagnosis of
hookworm infection was made with microscopic identifica-
tion of the characteristic ova in stool [6] performed by an
experienced parasitologist using three consecutive stool sam-
ples. Patients with extrapulmonary TB or intestinal parasitic
infection other than hookworm infection were excluded from
the study.
Patients were evaluated at the 4th month of therapy for
persistence of Mtb infection. All patients had clinical evalua-
tion, laboratory investigations, and imaging studies. Labora-
tory investigations included sputum culture on Lo¨wenstein–
Jensen medium, stool microscopic examination, complete
blood count, liver chemistry, kidney chemistry, fasting level
of serum glucose, and testing for antibody to human immun-
odeficiency virus. Imaging studies included abdominal ultra-
sonography and chest radiography. Long-term use of either
proton pump inhibitors or corticosteroids was defined as
use for 1 month or more during treatment for pulmonary TB.
Ethical considerations
The study was approved by the Faculty of Medicine Clinical
Research Ethical Committee (Assiut University), and was car-
ried out in accordance with the code of ethics of the World
Medical Association (Declaration of Helsinki). Before enroll-
ment in the study, all the participants signed a consent certifi-
cate. Before signing, they were able to discuss in detail with
the investigator the certificate subjects and the study aim.
The participants were clearly informed that refusing to par-
ticipate in the study will not affect having full benefit of the
available medical service and treatment. Data were collected
by personal interview with the participants taking in consid-
eration data confidentiality.
Statistical analysis
The data were entered and analyzed using the Statistical
Package for Social Sciences ((SPSS, Chicago IL, USA) for win-
dows, version 22). Results were expressed as mean ± standard
deviation or frequency (percentage) as appropriate. To com-
pare the distribution of demographic criteria between
patients with and without therapeutic failure of pulmonary
TB, we used Chi-square test. Predictors of the therapeutic fail-
ure of pulmonary TB were identified using univariate analysis
(Yates’ corrected Chi-square test) then multivariate analysis
(stepwise binary logistic regression) to assess the specific
effect of each predictor. Multivariate analysis included factors
with significant level (p < .05) in univariate analysis.
Results
The study included 231 patients diagnosed as having pul-
monary TB. The demographic criteria of the study population
with pulmonary TB are shown in Table 1. Their mean age was
42.7 ± 13.9 years old, with 26.8% of them being 40 years of age
Table 1 – The demographic criteria of the study population
with pulmonary tuberculosis (n = 231).
Age (y) 42.7 ± 13.9
Age (P40 y) 62 (26.8)
Gender (male) 133 (57.6)
Residence (rural) 159 (68.8)
Therapeutic failure of pulmonary TB 68 (29.4)
Hookworm infection 38 (16.5)
Corticosteroids (long-term use) 50 (21.6)
Proton pump inhibitors (long-term use) 48 (20.8)
Chronic obstructive pulmonary disease 60 (26)
Congestive heart failure 21 (9.1)
Obesity 43 (18.6)
DM 64 (27.7)
Renal insufficiency 25 (10.8)
Liver cirrhosis 36 (15.6)
Note. Apart from ‘‘Age”, all values are given as n (%).
DM = diabetes mellitus; n = number; TB = tuberculosis.
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therapeutic failure of pulmonary TB was 29.4%. Hookworm
infection was diagnosed among 16.5% of patients, and 27.7%
had diabetes mellitus (DM). None of the study population
had human immunodeficiency virus infection.
Table 2 shows the factors associated with the therapeutic
failure of pulmonary TB among the study population with
pulmonary TB. Using univariate analysis, it was found that
an age of 40 years or more, hookworm infection, long-term
use of corticosteroids, chronic obstructive pulmonary disease,
congestive heart failure, and DM were associated with the
therapeutic failure for pulmonary TB.
Using multivariate analysis of the factors associated with
the therapeutic failure of pulmonary TB on univariate
analysis, it was found that an age of 40 years or more [odds
ratio (OR) 8.4; 95% confidence interval (CI) 1.7–41.3; p = .009],
hookworm infection (OR 7.6; 95% CI 1.2–49.9; p = .034), and
DM (OR 5.9; CI 1.2–28; p = .027) were independently associated
with the therapeutic failure of pulmonary TB among the
study population with pulmonary TB (Table 3).Table 2 – Factors associated with the therapeutic failure of pulm
pulmonary tuberculosis (n = 231).
No therapeutic fa
Age (P40 y) 25 (15.3)
Gender (male) 97 (59.5)
Residence (rural) 108 (66.3)
Hookworm infection 17 (10.4)
Corticosteroids (long-term use) 30 (18.4)
Proton pump inhibitors (long-term use) 31 (19)
Chronic obstructive pulmonary disease 37 (22.7)
Congestive heart failure 12 (7.4)
Obesity 29 (17.8)
DM 39 (23.9)
Renal insufficiency 17 (10.4)
Liver cirrhosis 23 (14.1)
Note. All values are given as n (%).
DM = diabetes mellitus; n = number; TB = tuberculosis.
* Statistically significant.Discussion
Our study has revealed a high rate of therapeutic failure of
pulmonary TB (29.4%). This rate is much higher than expected
(10%) after 2 months of treatment with isoniazid, rifampin,
ethambutol, and pyrazinamide, followed by 4 months of
treatment with isoniazid and rifampin [2], and is modestly
higher than the rate (15%) reported by Ditah et al. [12]. How-
ever, this rate among our study population is very close to
that reported among the Korean patients (30%) [13]. This
observation reflects that we are facing difficulty in treating
pulmonary TB in our locality. Besides Mtb resistance to
antimicrobial therapy, other factors contributing to the rela-
tively high rate of the therapeutic failure have to be explored.
Among our study population with pulmonary TB, predic-
tors of the therapeutic failure of pulmonary TB were being
aged 40 years or more, hookworm infection, and DM. In
agreement with our study findings, advanced age was one
of the independent risk factors of the therapeutic failure of
pulmonary TB [12,14]. Several studies reported this associa-
tion with different discriminant points of age. The highest
point (55 years old or more) was reported as a predictor of
therapeutic failure of pulmonary TB by Mun˜oz-Sellart et al.
[15], while the lowest one (45 years old or more) was reported
by Cruz-Hervert et al. [16]. Inbetween, it was found that an
age of 50 years or more (OR3.11; 95% CI 1.17–8.26) [17], or
46 years or more (OR 6.71; 95% CI 1.61–28) [18] were predictors
of the therapeutic failure of pulmonary TB. Immunological
control of TB is based on CD4+ T-cell-produced gamma
interferon with subsequent activation of macrophages [19].
Immunosenescence encompasses progressive dysfunction
of both humoral and cellular immune functions contributing
to increased host susceptibility to TB [20]. Therapeutic failure
among older patients may be due to decreased absorption of
drugs associated with age-related physiological changes such
as altered gastric pH, modified gastric emptying rate, and
slower intestinal transit time; or it can be related to drug
intolerance with polytherapy [21].onary tuberculosis among the study population with
ilure (n = 163) Therapeutic failure (n = 68) p
37 (54.4) .001*
36 (52.9) .826
51 (75) .293
21 (30.9) .003*
20 (29.4) .036*
17 (25) .059
23 (33.8) .040*
9 (13.2) .025*
14 (20.6) .301
25 (36.8) .021*
8 (11.8) .514
13 (19.1) .337
Table 3 – Predictors of the therapeutic failure for pulmonary tuberculosis among the study population with pulmonary
tuberculosis (n = 231).
OR 95% CI p
Age (P40 y) 8.4 1.7–41.3 .009*
Hookworm infection 7.6 1.2–49.9 .034*
DM 5.9 1.2–28 .027*
CI = confidence interval; DM = diabetes mellitus; n = number; OR = odds ratio; TB = tuberculosis.
* Statistically significant.
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failure of pulmonary TB by Choi et al. [17] (OR 2.52; 95%
CI 1.27–5.01), Hongguang et al. [22] (OR 67; 95% CI 2–22.2),
and Mi et al. [23]. Experiments tracking the immune response
weekly showed lower gamma-interferon levels in the lungs of
diabetic mice at the critical 2-week time point when the lung
Mtb load is rising logarithmically after low dose aerosol chal-
lenge [24]. Diabetics had lower plasma levels of interleukin
(IL)-22 than nondiabetic TB patients. The potential signifi-
cance of reduced IL-22 in TB is unknown, but lower IL-22
was linked to impaired pulmonary epithelial barrier integrity
with Klebsiella pneumoniae infection [25]. In addition, periph-
eral blood monocytes from patients with DM (type-2) have a
reduced capacity to bind or ingest Mtb bacilli compared to
monocytes from euglycemic controls. This phenotype was
associated with poor glycemic control, and is attributable to
alterations in the complement pathway of opsonization
rather than monocyte phagocytic ability per se [26].
Hookworm infection was found to affect 16.5% of our
study population with pulmonary TB. This rate is lower than
that reported by both Elias et al. (28.3%) [27] and Abate et al.
(25%) [28] among the patients with TB. The outcome of Mtb
infection depends on the cell-mediated immunity. Interaction
of macrophages infected with Mtb with both CD4+ and CD8+
T-cells induces the release of cytokines leading to macro-
phage activation and, in most cases, control of the infection
[29]. Individual variation in susceptibility to TB is not fully
understood. Protection against TB is associated with
enhanced Th1 cell-mediated immune responses [30], while
susceptibility to the disease is associated with reduced Th1
type responses and/or enhanced Th2 responses with the
resulting high IL-4, IL-5, and IL-10 [31]. Responses of Th2 are
usually elicited by helminth infections [32]. It is becoming
increasingly evident that helminth infections, in addition to
stimulating marked Th2 responses, can induce suppressive
T-cell populations known as regulatory T-cells (Tregs) which
produce inhibitory cytokines (IL-10 and transforming growth
factor-beta) that suppress Th1 responses and interfere with
activation of effector T-cells [33]. Such Tregs could be induced
to regulate responses to pathogens [34]. Involvement of Tregs
in helminth-induced immunosuppression has been reported
[35,36].
Our study has some limitations. The sample size is rela-
tively small for extracting solid conclusions. Antimicrobial
sensitivity testing was not performed. However, our study
has some points in favor. The study is prospective and not a
retrospective one. To the best of our knowledge, it is the first
study to explore the relationship between hookworm infec-
tion and response to therapy of pulmonary TB.Conclusion
In conclusion, the rate of the therapeutic failure of pulmonary
TB is high in Egypt. Besides older age and DM, hookworm
infection can reduce the therapeutic response of pulmonary
TB. Screening for and control of DM and hookworm infection
among patients with pulmonary TB in Egypt may improve the
therapeutic response.Conflicts of interest
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